Benefits
Poststroke depression with apathy (Robinson 2009 small POSITIVE)
Robinson 2009 (PMID 19622685, J Neuropsychiatry Clin Neurosci 21(2):144-151) double-blind treatment of 13 patients with poststroke depression and apathy with nefiracetam. Reported significant improvement in apathy symptoms with nefiracetam vs placebo. POSITIVE small trial supporting potential utility in this specific clinical context. Limited by very small sample size.
Poststroke apathy RCT (Starkstein 2016 NEGATIVE FOLLOW-UP)
Starkstein 2016 (PMID 26915605, J Stroke Cerebrovasc Dis 25(5):1119-1127) randomized placebo-controlled double-blind efficacy study designed to replicate Robinson 2009. RESULTS: Treatment with nefiracetam DID NOT prove more efficacious than placebo in ameliorating apathy after stroke. Major limitation: very small randomized sample (of 2514 screened, only 144 confirmed eligible at 8-36 weeks poststroke). Authors concluded: 'pharmacological studies of apathy in stroke will require a large multicenter study and a massive sample of patients.' Failed replication of Robinson 2009.
Alzheimer's disease (NIH-sponsored Phase 2)
NIH/NINDS-sponsored Phase 2 trial NCT00001933 (Nefiracetam Therapy of Alzheimer's Type Dementia) completed. Tested whether nefiracetam can safely improve memory, thinking, and ADL in mild-moderate Alzheimer's. Mechanism: enhances acetylcholine-mediated and nicotinic receptor function. Results integrated into broader cholinergic dementia literature with mixed conclusions. Earlier small studies showed ~25% response at low dose, ~50% at higher dose.
Nicotinic acetylcholine receptor enhancement (mechanism)
Distinguishing feature among racetams: enhances NICOTINIC ACETYLCHOLINE RECEPTOR function. Different from typical racetams (AMPA, HACU) and from cholinesterase inhibitors. Theoretical basis for cognitive enhancement and possibly antiapathy effects. Mechanism interesting but clinical evidence mixed.
GABA-A modulation (anxiolytic potential)
Animal studies suggest nefiracetam has GABA-A receptor modulatory effects — possible anxiolytic mechanism. Theoretical relevance to combined mood + cognitive effects. Less clinically validated than other racetam mechanisms.
Mechanism of action
Nicotinic acetylcholine receptor enhancement
Nefiracetam enhances NICOTINIC ACh receptor activity — distinguishing it from cholinesterase inhibitors (which prevent ACh breakdown) and other racetams (which affect different mechanisms). Mechanism for proposed cognitive enhancement and antiapathy effects.
GABA-A receptor positive modulation
Modulates GABA-A receptors with possible anxiolytic effects. Mechanism for theoretical mood/anxiety benefits. Less robust than dedicated GABAergic anxiolytics (benzodiazepines).
Calcium channel modulation
Animal studies suggest nefiracetam modulates voltage-dependent and NMDA-coupled calcium channels — protecting neurons from calcium-mediated excitotoxicity. Mechanism for proposed neuroprotective effects in stroke models.
Cholinergic and glutamatergic enhancement
General cognitive enhancement via increased ACh release and modulated glutamatergic transmission. Mechanism similar to other racetams but with nicotinic emphasis.
Clinical trials
Double-blind treatment of apathy in poststroke depression (Robinson RG, Jorge RE, Clarence-Smith K, Starkstein S 2009, J Neuropsychiatry Clin Neurosci 21(2):144-151, doi:10.1176/jnp.2009.21.2.144, PMID 19622685).
13 patients with poststroke depression and apathy treated with nefiracetam vs placebo. Apathy and depression scales measured.
Nefiracetam showed SIGNIFICANT IMPROVEMENT in apathy symptoms vs placebo. Foundational small positive trial that motivated larger confirmatory study. Limited by small sample (n=13). Hypothesis-generating evidence for nefiracetam in poststroke apathy specifically.
Randomized placebo-controlled double-blind efficacy study (Starkstein SE, Brockman S, Hatch KK, Bruce DG, Almeida OP, Davis WA, Robinson RG 2016, J Stroke Cerebrovasc Dis 25(5):1119-1127, doi:10.1016/j.jstrokecerebrovasdis.2016.01.032, PMID 26915605).
Of 2514 patients screened, only 377 (15%) eligible after first screening, 233 declined, 144 assessed for apathy at 8-36 weeks poststroke. Final randomized sample very small.
NEFIRACETAM DID NOT prove more efficacious than placebo in ameliorating apathy after stroke. NEGATIVE RCT. Failed replication of Robinson 2009 small positive study. Authors concluded: 'pharmacological studies of apathy in stroke will require large multicenter study and massive sample of patients' — acknowledging trial design challenges. Important counter-evidence to earlier positive findings.
NIH/NINDS-sponsored Phase 2 trial (NCT00001933, Nefiracetam Therapy of Alzheimer's Type Dementia).
Mild-to-moderate Alzheimer's disease patients with caregiver and designated representative. Acute safety and antidementia efficacy tested in double-blind placebo-controlled parallel-groups design.
Nefiracetam enhances activity of nicotinic acetylcholine receptors (in contrast to cholinesterase inhibitors). Earlier small studies showed ~25% improvement at low dose, ~50% at higher dose in mild AD. Comprehensive Phase 2 results integrated into broader literature with mixed conclusions about clinical utility. Did not result in commercial drug approval.
About this ingredient
Nefiracetam (N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide, DM-9384, brand name Translon) is a PYRROLIDONE RACETAM developed by Daiichi Pharmaceutical Co. (Japan) in the 1980s. Distinguishing chemical feature: dimethylphenyl substitution providing distinct pharmacology vs other racetams.
Initially developed for cognitive disorders; marketed in Japan as TRANSLON (subsequently withdrawn/discontinued). UNIQUE PHARMACOLOGY among racetams: enhances NICOTINIC ACETYLCHOLINE RECEPTOR function (most racetams affect AMPA, HACU, or general cholinergic systems — nefiracetam specifically targets nicotinic receptors). Additional mechanisms: GABA-A receptor positive modulation, calcium channel modulation (voltage-dependent and NMDA-coupled), general cholinergic and glutamatergic enhancement.
CLINICAL EVIDENCE: ROBINSON 2009 PMID 19622685 small positive RCT in poststroke depression with apathy (n=13) — foundational positive evidence. STARKSTEIN 2016 PMID 26915605 larger replication RCT FAILED to confirm efficacy — negative result with practical trial design challenges noted (only 144 eligible from 2514 screened). NIH NCT00001933 Phase 2 Alzheimer's trial completed with mixed results integrated into broader cholinergic dementia literature.
Earlier smaller AD studies showed dose-dependent response (~25% low dose, ~50% high dose). REGULATORY STATUS: Was prescription drug in Japan (Translon) — subsequently withdrawn/unavailable. Approved in Russia for cognitive disorders.
Not FDA-approved; sold as 'research compound' / nootropic supplement in US (gray zone). EVIDENCE: 2/5 reflects: (1) Robinson 2009 PMID 19622685 small positive poststroke apathy RCT, (2) Starkstein 2016 PMID 26915605 NEGATIVE replication RCT, (3) NIH-funded Alzheimer's Phase 2 with mixed conclusions, (4) unique nicotinic ACh receptor mechanism, (5) Japanese drug market withdrawal indicating commercial unviability, (6) limited modern rigorous Western RCTs, (7) gray regulatory status in US. SAFETY: Generally well-tolerated; long-term safety beyond clinical trial durations less characterized.
Best positioned as: (a) RESEARCH-INTEREST compound for poststroke cognitive/apathy contexts pending larger trials, (b) ALZHEIMER'S adjunct historically (where studied) — modest evidence at best, (c) NOT recommended for general nootropic use based on mixed evidence and product withdrawal, (d) UNIQUE NICOTINIC mechanism with possible future therapeutic potential, (e) RESEARCH COMPOUND in US warrants regulatory caution. Honest framing: nefiracetam evidence is mixed — Robinson 2009 small positive, Starkstein 2016 negative replication. The Japanese market withdrawal of Translon and absence of commercial development partner is practically significant.
Unique nicotinic ACh receptor mechanism is interesting but clinical translation incomplete. Reasonable for medical-context research; not recommended for general nootropic enhancement based on rigor of evidence.